Faculty profile

Barry Rosen

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Barry Rosen

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
No publications since 2021.
Principal investigator on 2 research grants (2 CIHR), most recently in 2013.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

2,064

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Fallopian Tube Glucocorticoid Inflammation Molecular Biology Ovarian Cancer Ovulation Serous Cancer

Latest papers

Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.
Proceedings of the National Academy of Sciences of the United States of America · 2021
The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021
Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2020

All 84 publications

Latest funding

Cancer Prevention in Women with a BRCA1 or BRCA2 Mutation: A Follow-up Genetic Counselling Telephone Intervention (PREVENT Trial)
CIHR · 2014 · Co-investigator
$597,049
Sustained ovulation-associated inflammatory signaling in fallopian tube epithelium as a predisposing factor of serous carcinoma
CIHR · 2013 · Principal investigator
$483,754
The effect of prophylactic salpingo-oophorectomy on markers of health in women who carry a BRCA mutation
CIHR · 2012 · Co-investigator
$382,243

All 4 grants and awards

84 publications.

Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.

Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, Tu D, Parulekar WR, Nankivell M, Kehoe S, Chi DS, Levine DA, Bernardini MQ, Rosen B, Oza A, Brown M, Neel BG

Proceedings of the National Academy of Sciences of the United States of America2021

DOI: 10.1073/pnas.2026663118 PMID: 34161278

The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer.

Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod SA, May T

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2021

DOI: 10.1002/ijgo.13542 PMID: 33326624

Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2020

DOI: 10.1136/ijgc-2019-001141 PMID: 32354794

Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.

Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM

JAMA network open2019

DOI: 10.1001/jamanetworkopen.2019.8420 PMID: 31390031

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation

Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL

Gynecologic Oncology2018103 citations

DOI: 10.1016/j.ygyno.2018.05.011

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.

Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Hogdall CK, Høgdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Jung AY, Karlan BY, Kellar M, Kiemeney LA, Kiong Lim B, Kjaer SK, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lele S, Lester J, Levine DA, Li Z, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LFAG, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Odunsi K, Olson SH, Orlow I, Orsulic S, Paul J, Pejovic T, Pelttari LM, Permuth JB, Pike MC, Poole EM, Rosen B, Rossing MA, Rothstein JH, Runnebaum IB, Rzepecka IK, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tworoger SS, van Altena AM, Vergote I, Vestrheim Thomsen LC, Vierkant RA, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu AH, Wu X, Xiang YB, Yang H, Zheng W, Ziogas A, Lee AW, Pearce CL, Berchuck A, Schildkraut JM, Ramus SJ, Monteiro ANA, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PDP, Goode EL, Phelan CM

PloS one2018

DOI: 10.1371/journal.pone.0197561 PMID: 29979793

The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.

May T, Stewart JM, Bernardini MQ, Ferguson SE, Laframboise S, Jiang H, Rosen B

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2018Senior author

DOI: 10.1002/ijgo.12376 PMID: 29095487

Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?

McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA, Hereditary Ovarian Cancer Clinical Study Group

Gynecologic oncology2017

DOI: 10.1016/j.ygyno.2017.02.032 PMID: 28314588

Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.

Akbari MR, Zhang S, Cragun D, Lee JH, Coppola D, McLaughlin J, Risch HA, Rosen B, Shaw P, Sellers TA, Schildkraut J, Narod SA, Pal T

Familial cancer2017

DOI: 10.1007/s10689-017-9973-1 PMID: 28176205

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.

May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, Ghatage P

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2017

DOI: 10.1097/igc.0000000000000946 PMID: 28441250

Something wrong or missing on this profile? Suggest a correction

Barry Rosen

Research

Latest papers

Latest funding

Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.

The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer.

Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.

Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.

The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.

Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?

Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.

Cancer Prevention in Women with a BRCA1 or BRCA2 Mutation: A Follow-up Genetic Counselling Telephone Intervention (PREVENT Trial)

Sustained ovulation-associated inflammatory signaling in fallopian tube epithelium as a predisposing factor of serous carcinoma

The effect of prophylactic salpingo-oophorectomy on markers of health in women who carry a BRCA mutation

Sustained ovulation-associated inflammatory signaling in fallopian tube epithelium as a predisposing factor of serous carcinoma

Frequent collaborators

Joanne Kotsopoulos

Andrea Eisen

Andrea Eisen

Angela Brooks-Wilson

Angela Brooks-Wilson

Kelly Metcalfe

Vasily Giannakeas

Amit Oza

Laurie Elit

Allan Covens

Sarah Ferguson

Stephanie Lheureux

Michael Fung-Kee-Fung

Mary Gospodarowicz

Tony Panzarella

Heather Shapiro

Donna Stewart

Konstantin Shestopaloff

Jacob McGee

Robin Mcleod

Michael Milosevic

Jonathan Irish

Mark Minden

Jacques Simard

Louise Bordeleau

David Chitayat